What was known before {#section21-2054358119828386}
=====================

In the hemodialysis (HD) population, it has been shown that high-sensitivity cardiac troponin (hs-cTnT) falls during and shortly after HD, before rising back to baseline levels.

What this adds {#section22-2054358119828386}
==============

This study demonstrates a larger drop in high-sensitivity cardiac troponin (hs-cTnT) levels during CRRT, which must be taken into consideration when interpreting cardiac troponin changes in this setting. Further studies are required to see whether these findings extend to different troponin assays and in patients with established myocardial injury.

Introduction {#section23-2054358119828386}
============

Acute kidney injury (AKI) is common among patients admitted to the intensive care unit (ICU), with 57% of such patients meeting the diagnostic criteria for AKI.^[@bibr1-2054358119828386]^ Among patients admitted to the ICU with AKI, dialysis may be required, and continuous renal replacement therapy (CRRT) is often the modality of choice when hemodynamic instability is an issue. Cardiovascular disease is a significant contributor to AKI-associated mortality.^[@bibr2-2054358119828386]^ Diagnosing an acute coronary syndrome (ACS) in this setting can be challenging as patients may present with nonspecific symptoms, and as many as 25% of patients can have silent ischemia.^[@bibr3-2054358119828386]^ Furthermore, critically ill patients are often sedated and intubated. As such, cardiac biomarkers are relied upon to diagnose myocardial injury. In addition, interpretation of cardiac troponins (cTns) can be more difficult in patients with renal disease. For example, patients with chronic kidney disease (CKD) and AKI have been noted to have stable but elevated cTn levels.^[@bibr4-2054358119828386]^ Such cTn elevations have been demonstrated to have long-term prognostic implications for cardiovascular mortality, but are not necessarily a marker of acute myocardial injury.^[@bibr5-2054358119828386]^ As such, dynamic changes in cTn remain key to diagnosing an ACS, both in the general population and in patients with AKI and CKD. The impact of renal replacement therapy (RRT) on troponin levels poses another challenge. The molecular weights of cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are 24 kDa and 36 kDa, respectively. The pore size of filters used for CRRT is typically approximately 30 kDa. As such, one would expect relatively little clearance of these molecules. Data in the chronic hemodialysis (HD) population have shown variable results. One study employing non-high-sensitivity cTn demonstrated cTn stability or rise following HD.^[@bibr6-2054358119828386]^ Another study using high-sensitivity cTnT (hs-cTnT) demonstrated no reduction after conventional HD, but interestingly a significant reduction in serum levels after hemodiafiltration, particularly with a longer duration.^[@bibr7-2054358119828386]^ In a study of 10 chronic HD patients, we recently demonstrated that hs-cTnT falls by approximately 11% during and shortly after HD, before rising back to baseline levels 11 hours later.^[@bibr8-2054358119828386]^ The purpose of this study was to describe the influence of CRRT on hs-cTnT levels among patients admitted to the ICU with AKI.

Materials and Methods {#section24-2054358119828386}
=====================

This was a single-center, prospective observational study conducted at the Jewish General Hospital (Montreal, Quebec, Canada). Patients included were those admitted to the ICU with AKI undergoing CRRT (initiated at the discretion of the attending intensivist). Exclusion criteria included patients with ACS, post-cardiac surgery patients, and those with end-stage renal disease (ESRD). Patient demographics, reason for ICU admission, reason for AKI, and outcome were recorded. All measures of hs-cTnT were blinded to the treating team. Five patients were on continuous veno-venous hemodiafiltration, one patient was on continuous veno-venous hemodialysis, and 4 patients were on continuous veno-venous hemofiltration. The CRRT parameters are included in [Table 1](#table1-2054358119828386){ref-type="table"}. Prismaflex ST150 dialyzers (Baxter Healthcare, Deerfield, Illinois) were used in all patients, and CRRT prescription and dosing was at the discretion of the treating intensivist. The study received ethics approval from the hospital's research ethics board and was adherent to the Declaration of Helsinki.

###### 

Patient Characteristics.

![](10.1177_2054358119828386-table1)

  Patient   Age (y)   Sex   Patient weight (kg)   Cause of renal failure   Reason for ICU admission                          Duration of CRRT (h)   Creatinine at CRRT initiation (µmol/L)   Urine output (cc/24 h)   Dialysate rate (cc/kg/h)   Replacement rate^[a](#table-fn2-2054358119828386){ref-type="table-fn"}^ (cc/kg/h)   Ultra-filtration (cc/h)   Anticoagulation          Outcome
  --------- --------- ----- --------------------- ------------------------ ------------------------------------------------- ---------------------- ---------------------------------------- ------------------------ -------------------------- ----------------------------------------------------------------------------------- ------------------------- ------------------------ ----------------
  1         67        M     85                    ATN                      Intra-abdominal sepsis                            41                     410                                      \<200                    23.5                       23.5                                                                                0                         Heparin (800-1000 U/h)   Renal recovery
  2         59        F     61.5                  ATN                      Pneumosepsis with multiorgan dysfunction          25                     228                                      \<200                    None                       32.5                                                                                0                         None                     Died
  3         58        M     196                   ATN                      Sepsis and hypercapnic respiratory failure        38                     593                                      \<200                    10.2                       None                                                                                0                         Heparin (800-1400 U/h)   IHD
  4         49        F     88                    ATN                      Post-surgical sepsis and hemorrhage               66                     555                                      \<200                    22.7                       22.7                                                                                0                         None                     Died
  5         68        M     111                   ATN                      Post-surgical sepsis                              56                     246                                      \<200                    18                         18                                                                                  0                         None                     IHD
  6         86        M     99                    ATN                      Ascending cholangitis                             27                     668                                      \<200                    15                         15                                                                                  50                        Heparin (400-500 U/h)    Died
  7         77        F     108.5                 ATN                      Urosepsis                                         63.5                   558                                      \<200                    None                       27.6                                                                                25                        None                     IHD
  8         36        F     82.5                  ATN                      Eclampsia and hemorrhagic shock                   65                     401                                      \<200                    None                       24.2                                                                                100                       None                     IHD
  9         61        M     82                    ATN                      Sepsis                                            61                     288                                      450                      24.4                       24.4                                                                                100                       None                     Died
  10        29        M     127                   ATN                      Hemophagocytic lymphohistiocytosis and lymphoma   72                     600                                      \<200                    None                       7.9                                                                                 50                        None                     Died

*Note.* ICU = intensive care unit; CRRT = continuous renal replacement therapy; ATN = acute tubular necrosis; IHD = intermittent hemodialysis; CKD = chronic kidney disease.

Pre-filter replacement with 200 cc/h post-filter replacement.

Baseline hs-cTnT was measured prior to initiation of CRRT (mean of 3.9 hours prior to initiation with SD of 3.2), within 6 hours of initiation, and subsequently, approximately every 6 hours. The exact frequency of blood collection was at the discretion of ICU nursing staff based on routine clinical care. Given the variable duration on CRRT, patients had varying number of measurements. The hs-cTnT was determined using a fifth-generation hs-cTnT immunoassay with a coefficient of variance \<10% at the 99th percentile (Roche Diagnostics, cat no. 05092744). Creatinine and albumin were also measured with each collection (Roche Diagnostics, cat no. 03263991190 and 11815148216).

To standardize time of collection, analytes were grouped into time intervals: 5 to 10 hours, 11 to 15 hours, 16 to 20 hours, and 21 to 30 hours post-initiation of CRRT. Mean change in analyte concentration and 95% confidence interval was determined at each time interval relative to baseline. Paired *t* tests were used to determine statistical significance of within-patient differences over time (Microsoft Excel).

Results {#section25-2054358119828386}
=======

Ten patients were enrolled in this study (6 males and 4 females) ([Table 1](#table1-2054358119828386){ref-type="table"}). Median age was 59 years (range = 29-86). All patients were admitted to the ICU with shock, with sepsis being the etiology in 80%. Mean duration of CRRT in this cohort was 51.5 hours with a range of 25 to 72 hours. Mean creatinine prior to CRRT initiation was 454.7 µmol/L (SD of 161.3). Five patients died, 1 had sufficient renal recovery to discontinue RRT, and 4 patients were transitioned to intermittent HD post-ICU discharge.

There was a significantly lower mean hs-cTnT during CRRT in each time interval, when compared with levels prior to the start of dialysis (*P* \< .05) ([Figure 1](#fig1-2054358119828386){ref-type="fig"}). There was a 42% decrease in hs-cTnT at 5 to 10 hours post-CRRT initiation, with stable levels thereafter ([Figure 1](#fig1-2054358119828386){ref-type="fig"}). As expected, creatinine steadily declined after CRRT initiation in all 4 time intervals (*P* \< .05), while there was no significant change in albumin levels during CRRT. In the 3 patients in whom hs-cTnT was measured after CRRT discontinuation (5-10 hours after last blood work drawn during CRRT), a rise in hs-cTnT was noted (*P* = .057).

![Change in analyte levels and corresponding confidence intervals over the course of CRRT.\
*Note.* CRRT = continuous renal replacement therapy.](10.1177_2054358119828386-fig1){#fig1-2054358119828386}

Discussion {#section26-2054358119828386}
==========

This study has demonstrated significant clearance of hs-cTnT in patients undergoing CRRT. By 5 to 10 hours post-initiation of CRRT, hs-cTnT levels decreased by 42% from baseline and remained stable thereafter. In patients with available blood work, there appeared to be a rise in hs-cTnT after cessation of CRRT, although this did not reach statistical significance.

Stably elevated troponin levels have been demonstrated in patients with CKD and AKI, likely reflecting subclinical coronary artery disease.^[@bibr4-2054358119828386]^ As such, dynamic changes in cTn are important to diagnose ACS. This study, in conjunction with our previous investigation in HD patients, offers some insight into the influence of dialysis on cTn levels. While an 11% reduction in mean hs-cTnT was demonstrated during HD,^[@bibr8-2054358119828386]^ we noted a much larger reduction in CRRT patients. This likely reflects the longer duration of dialysis and possibly the greater convective clearance of larger molecular weight substances such as hs-cTnT (and/or their degradation products, which have been shown to cross-react with the hs-cTnT assay).^[@bibr9-2054358119828386]^ This is also consistent with the study by Cardinaels and colleagues^[@bibr7-2054358119828386]^ demonstrating greater reduction in serum levels of hs-cTnT with longer duration of hemodiafiltration.

Clinical guidelines currently recommend using a 20% or more change in cTn levels from baseline to diagnose ACS.^[@bibr10-2054358119828386]^ Thus, the greater than 40% reduction in troponin observed in this study can mask an ACS. Alternatively, a lack of fall in troponin levels upon CRRT initiation should be concerning for myocardial injury. It is important to note that a steady state appears to be reached 5 to 10 hours after CRRT initiation, after which a new baseline hs-cTnT is reached, assuming no further interruptions in CRRT. One might therefore infer that myocardial injury occurring 5 to 10 hours after starting CRRT should manifest as a rise in hs-cTnT above this new baseline.

To our knowledge, this is the first study showing a significant reduction in cTns after CRRT initiation, in keeping with the hs-cTnT studies in HD patients. Nevertheless, there are several study limitations. First, this was a single-center study with a small sample size and a lack of homogeneity in CRRT prescriptions. Second, only hs-cTnT was studied, so the results cannot be extrapolated to non-high-sensitivity troponin assays or to Troponin I assays. Third, we cannot say with certainty whether the reduction was due to clearance of TnT or of its metabolites which can interfere with the assay. It would be interesting to measure effluent concentrations of hs-cTnT and its metabolites in future studies to explore this further. Fourth, we cannot rule out the possibility of subclinical cardiac ischemia in some patients prior to initiation of CRRT, which could have partly explained the declining hs-cTnT observed after CRRT initiation. Finally, the majority of patients received fairly high doses of CRRT, which likely influenced the magnitude of hs-cTnT removal and must be taken into consideration when anticipating changes in levels. Despite these limitations, our study is novel and sheds light on the highly clinically relevant question of what happens to hs-cTnT levels in patients on CRRT. Further studies are warranted to confirm our findings, and to determine whether this effect is seen with different troponin assays and how this affects post-ACS and post-cardiac surgery patients.

To conclude, hs-cTnT levels decrease within 5 to 10 hours of CRRT initiation. Consequently, interpretation of troponin changes during CRRT must take into consideration the timing of CRRT initiation relative to the timing of sample collection.
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